Jazz Pharmaceuticals (JAZZ) Free Cash Flow (2010 - 2026)

Jazz Pharmaceuticals' Free Cash Flow history runs 17 years deep, the most recent figure standing at $331.0 million for Q1 2026.

• On a quarterly basis, Free Cash Flow fell 22.99% year-over-year to $331.0 million in Q1 2026; TTM through Mar 2026 was $1.2 billion, a 21.4% decrease from a year earlier, with the FY2025 full-year figure at $1.3 billion, down 4.48% from the prior year.
• Free Cash Flow retreated to $331.0 million in Q1 2026 per JAZZ's latest filing, from $1.2 billion in the prior quarter.
• Across five years, Free Cash Flow topped out at $1.2 billion in Q4 2025 and bottomed at -$382.6 million in Q3 2025.
• The 5-year median for Free Cash Flow is $316.9 million (2023), against an average of $313.3 million.
• Across the five-year window, Free Cash Flow soared 629.43% in 2022 and sank 198.63% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at $337.6 million in 2022, then tumbled by 46.33% to $181.2 million in 2023, then surged by 112.64% to $385.3 million in 2024, then soared by 201.54% to $1.2 billion in 2025, then slumped by 71.51% to $331.0 million in 2026.
• Per Business Quant, the three latest JAZZ Free Cash Flow figures stand at $331.0 million (Q1 2026), $1.2 billion (Q4 2025), and -$382.6 million (Q3 2025).